Adhera Therapeutics (Adhera Therapeutics) Change In Working Capital : $0.63 Mil (TTM As of Sep. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics Change In Working Capital?

Adhera Therapeutics's change in working capital for the quarter that ended in Sep. 2023 was $1.29 Mil.

Adhera Therapeutics's change in working capital for the fiscal year that ended in Dec. 2022 was $0.20 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Adhera Therapeutics Change In Working Capital Historical Data

The historical data trend for Adhera Therapeutics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adhera Therapeutics Change In Working Capital Chart

Adhera Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

-1.48

0.48

1.40

0.01

0.20

Adhera Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Working Capital	Get a 7-Day Free Trial															0.87	-0.69	0.04	-0.02	1.29

Adhera Therapeutics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.63 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Adhera Therapeutics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Adhera Therapeutics (Adhera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Innovation Parkway, Baton Rouge, LA, USA, 70820

Website

https://www.adherathera.com

Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.

Executives

Zahed Subhan	director	8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness	director	8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: Chief Executive Officer	549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley	officer: SVP Finance & Accounting	5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan	director	812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague	officer: Chief Financial Officer	C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell	director	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato	officer: CEO	400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris	director	805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein	officer: Chief Legal Officer	C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah	officer: Chief Financial Officer	10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson	officer: Chief Commercial Officer	2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif	officer: Chief Operating Officer	21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679